#GNMX #NBRV #TGTX should investors buy these 3 beat down biotech?
- #GNMX Aevi Genomics Medicine, Inc
- Year to date performance -76.06%
- Stock up +20.97% after hours, after Schedule 13D from Children's Hospital of Philadelphia Foundation (CHOP) took 30.08% stake http://archive.fast-edgar.com//20171017/AIA2TG2CZZ22BZZ222JM2ZZE45U32B22N292/
2. #NBRV Nabriva Therapeutics PLC
- Still positive on YTD performance +11.74%
- Investors were disappointed on the big raised secondary after success Phase 3.
- Stock took a beating, see chart for support levels
3. #TGTX TG Therapeutics Inc
- The recently selling off due to FDA meeting update on GENUINE phase 3 trial http://ir.tgtherapeutics.com/releasedetail.cfm?ReleaseID=1043983
- Stock YTD performance still up +81.18%